Overview
Transcutaneous and EUS-guided radiofrequency ablation are both modern modalities to apply in the managemnet of various malignancies.
In the current study the investigators aim to study the technical feasibility, patient safety and clinical efficacy of EUS-RFA for the treatment of pancreatic insulinoma.
Description
Patients (P): Alla patients referred to Sahlgrenska University Hospital for the diagnostic work-up and management of a suspected pancreatic insulinoma.
Intervention (I): EUS-RFA
Control group (C): Patients with insulinoma treated with conventional surgery during the time frame 2018-2025 (historic controls).
Outcome (O):
- Technical feasibility
- Patient safety
- Clinical efficacy (follow-up with biochemistry and imaging at 3, 6, 12, and 24 months post-EUS-RFA).
Eligibility
Inclusion Criteria:
- Insulinoma verified by pathology (often from EUS-FNB-sampling)
Exclusion Criteria:
- Patients unwilling to participate
- Patients unable to understand and obtain written informed conscent
- Severe comorbidity
